New Therapeutic Tools in Diabetic Retinopathy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 5207
Special Issue Editor
Special Issue Information
Dear Colleagues,
The prevalence of diabetes mellitus (DM) is increasing worldwide, leading to an increase in DM-related microvascular complications such as diabetic retinopathy (DR) and diabetic macular edema (DME). DR and DME are chronic and sight-threatening diseases that significantly impact on patients’ quality of life. Microvascular abnormalities and occlusion due to chronic hyperglycemia are considered as the main etiologies of DR and DME, associated with various growth factors. Among these growth factors, vascular endothelial growth factor (VEGF) causes an abnormal occlusive function of the inner blood–retinal barrier and causes the accumulation of extracellular interstitial fluid. Since anti-VEGF agents were introduced based on these mechanisms, intravitreal injections of anti-VEGF agents have replaced laser photocoagulation as the standard treatment for most patients with DME and may improve DR severity. However, due to DR being a multifactorial disease with a complex pathophysiology, there are still great efforts needed to elucidate the role of retinal microvasculature complications during the progression of DR to produce better therapeutic options and outcomes. This Special Issue of the International Journal of Molecular Sciences focuses on the new therapeutic tools in DR and welcomes both original research articles and review papers that deal with the molecular mechanisms pathology in DR and DME to increase our knowledge and support better treatment tools for people with DR.
Dr. Kihwang Lee
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diabetes mellitus
- diabetic retinopathy
- diabetic macular edema
- anti-VEGF
- non-proliferative diabetic retinopathy
- proliferative diabetic retinopathy
